|
Back
Proteomic analysis
of homeopathic glutamanergic neurotoxicity and
protection
Principal Investigator: Aryan Namboodiri PhD
Affiliations: Assistant Research Professor,
Department of Anatomy, Physiology and Genetics, Uniformed Services
University of the Health Sciences
Background: Glutamate, the major excitatory
neurotransmitter in the brain, is a causative agent in neuronal damage
associated with a variety of neuropathological conditions including
stroke, progressive neurodegenerative diseases (such as Alzheimers and
Parkinsons diseases) and neuroAIDS. This damage is mediated by several
classes of glutamate receptors in two major families of receptors, one
associated with ionic conductance and one with metabotropic areas. The
former group of receptors is associated with calcium influx as the source
of the damage. There is evidence that ultra-low doses of glutamate can be
neuroprotective when brain injury is occurs. Thus, there appears to be a
balance between the neuroprotective and neurotoxic action of certain
agents as a function of dose or concentration. Glutamate and N-acetylaspartylglutamate
[NAAG] are two such agents that share this biology and are therefore
worthy of more investigation. Similarly, the homeopathic remedy, Arnica
Montana, also has demonstrated long-term neuroprotection in prior studies
of brain injury.
Hypotheses: Neuroprotection from low and
ultra-low doses of glutamate, NAAG and Arnica involves underlying
quantitative and qualitative changes in brain proteins that can be
determined by proteomic methods. There is a specific, non-ribosomal
dipeptide synthetase enzyme in the nervous system that acts to couple N-acetylaspartate
and glutamate to form NAAG and this enzyme is involved in homeopathic
neuroprotective action.
Methods and materials: An in vivo rat
excitotoxic-lesion model of neuronal damage using quinolinate will be used
to study [via histopathological and immunohistochemical screening] what
doses of the agent are effective and what degree of neuroprotection can be
obtained with low dose NAAG and glutamate. The striatum will be isolated
in order to identify the constituent protein pattern between study and
control groups, and unknown proteins will be identified using genetic and
protein databases. In addition, efforts will be made via radiolabelled
substrate and rat brain homogenates to determine if NAA is conjugated to
glutamate to form NAAG by a non-ribosomal enzyme system.
Anticipated results: Preliminary work
suggests that both hypotheses cited will be true, and that key protein
targets which are modified by low-dose neuroprotective treatments, and the
enzyme responsible for the biosynthesis of NAAG will be isolated and
purified sufficiently for characterization and antibody generation. The
mechanism of low-dose and homeopathic agents in these processes as
neuroprotectants will then be discovered.
Relationship to SIIB mission and healing: The
ability to utilize a homeopathic remedy in the treatment and possible
amelioration of neurological injuries would be an outstanding achievement.
The implications in both peacetime and war are evident.
Publication: From
Moffett, John R & Namboodiri, MA Aryan, "Tryptophan and the
immune response", Immunology and Cell Biology (2003), 81, 247-265,
reproduced with permission.
PDF Link
|